Draft:Semaltara


Semaltara
Clinical data
Trade namesSemaltara
Routes of
administration		Oral
Legal status
Legal status
  • In general: ℞ (Prescription only)

Semaltara is a prescription medication containing semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, used for the treatment of type 2 diabetes mellitus. It is an oral tablet formulation developed and marketed by the Russian pharmaceutical company Promomed.[1]

The drug was registered in the Russian Federation in 2025 and became the first domestically produced oral semaglutide following the withdrawal of the reference product Rybelsus from the Russian market.[2][3]

Medical use

Semaltara is indicated for improving glycaemic control in adults with type 2 diabetes mellitus as an adjunct to diet and physical activity.[4]

Pharmacology

Semaglutide is a long-acting analogue of human glucagon-like peptide-1 (GLP-1). It increases glucose-dependent insulin secretion, suppresses inappropriate glucagon release, and slows gastric emptying. These effects contribute to improved glycaemic control and may also reduce appetite and body weight.

The pharmacological properties of oral semaglutide have been extensively studied in international clinical trials of the reference drug Rybelsus.[5]

Formulation and dosage

Semaltara is supplied as oral tablets in the following strengths:

  • 3 mg
  • 7 mg
  • 14 mg

The dosing regimen follows standard titration protocols established for oral semaglutide formulations.[6]

References

  1. ^ "The copycat brands that are replacing Ozempic in Russia". www.ft.com. Retrieved 2026-01-19.
  2. ^ "Promomed registers Russia's first semaglutide tablets". GxP News.
  3. ^ "Russia Diabetes Market Size, Share, Forecast". Spherical Insights. Retrieved 2026-01-19.
  4. ^ "Promomed registers Russia's first semaglutide tablets". GxP News.
  5. ^ "Semaglutide (oral route)". Mayo Clinic.
  6. ^ "Promomed registers Russia's first semaglutide tablets". GxP News.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.